DRX-065 is a stabilized and deuterated R-enantiomer of pioglitazone. DRX-065 has pharmacological properties desirable for the treatment of NASH (mitochondrialfunction modulation, non-steroidal anti-inflammatory effects, and glucose lowering effects) with
Z640 an aPKC agonist. Z640 was further confirmed as a non‑selective aPKC agonist that can activate the kinase activity of both PKCι and PKCζ. In the cell‑based assay, Z640 was found to protect neuronal cell lines from amyloid‑β (Aβ) oligomer‑induced cell death by reducing reactive oxygen species production and restore mitochondrialfunction. In addition, Z640 could reduce Aβ40 generation in a dose‑dependent manner and shift amyloid precursor protein processing towards the non‑amyloid pathway
Decylubiquinone is an analog of ubiquinone. It increases mitochondrialfunction in synaptosomes. Decylubiquinone inhibits the redox-activated mitochondrial permeability transition.